Get the Stockscreener App
88.16
2.93%
-2.23
Bright Minds Biosciences Inc stock is traded at $88.16, with a volume of 15,106.
It is down -2.93% in the last 24 hours and up +4.12% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$90.39
Open:
$89.71
24h Volume:
15,106
Relative Volume:
0.07
Market Cap:
$853.12M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-66.90
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
-0.30%
1M Performance:
+4.12%
6M Performance:
+193.64%
1Y Performance:
+171.81%
1-Day Range:
$87.66
$89.83
1-Week Range:
$81.72
$91.00
52-Week Range:
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
87.66 | 879.69M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.83 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.88 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Price-Driven Insight from (DRUG) for Rule-Based Strategy - Stock Traders Daily
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Nigeria
New epilepsy study tests drug for adults whose seizures resist treatment - Stock Titan
Volume Summary: How Bright Minds Biosciences Inc. stock performs in high volatility markets - Bộ Nội Vụ
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Bright Minds Biosciences Stock Topped the Market on Monday - MSN
Bright Minds Biosciences closes $175 million public offering By Investing.com - Investing.com Nigeria
Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen - MarketBeat
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline - TipRanks
Bright Minds prices $175M stock offering - MSN
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Bright Minds Biosciences Closes its US$175 Million Public Offering - marketscreener.com
McMillan Advises Bright Minds Bioscience on its USD$175 Million Prospectus Offering - McMillan LLP
Bright Minds Biosciences closes $175 million public offering - Investing.com
Bright Minds Biosciences Closes $175.1 Million Stock Offering - marketscreener.com
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering - manilatimes.net
Star TribuneBright Minds Biosciences Announces Closing of US$175 Million Public Offering - FinancialContent
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) launches $175M equity raise for trials - Stock Titan
Can Bright Minds Biosciences Inc. stock sustain free cash flow growthBreakout Watch & High Conviction Investment Ideas - ulpravda.ru
How Bright Minds Biosciences Inc. stock responds to policy changesWeekly Volume Report & Daily Oversold Bounce Ideas - Улправда
Bright Minds Biosciences slips after increased $175 mln stock sale - TradingView — Track All Markets
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program - TipRanks
Bright Minds Biosciences prices public offering at $90 per share By Investing.com - Investing.com Nigeria
Bright Minds Biosciences prices $175 million public offering By Investing.com - Investing.com Nigeria
Why Bright Minds Biosciences Inc. stock is popular among millennialsSector ETF Performance & AI-Driven Stock Forecast Models - Улправда
Bright Minds Biosciences stock price target raised to $147 by BTIG By Investing.com - Investing.com Canada
Bright Minds Biosciences prices public offering at $90 per share - Investing.com
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock - The Manila Times
Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share - marketscreener.com
Bright Minds Biosciences launches $100 million public offering - MSN
Bright Minds Biosciences Ends Equity Distribution Deal With Piper Sandler and Cantor - TipRanks
Form FWP BRIGHT MINDS BIOSCIENCES Filed by: BRIGHT MINDS BIOSCIENCES INC. - StreetInsider
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating - Seeking Alpha
Crude Oil Down 2%; ISM Services PMI Surges In December - Benzinga
Why Did DRUG Stock Rocket 51% Today? - Asianet Newsable
Bright Minds Biosciences falls after $100 mln equity offering launched - TradingView — Track All Markets
Bright Minds Biosciences stock price target raised to $147 by BTIG - Investing.com Nigeria
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Bright Minds Biosciences launches $100 million public offering By Investing.com - Investing.com Nigeria
Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline - TipRanks
Will Bright Minds Biosciences Inc. stock deliver shareholder value - ulpravda.ru
Bright Minds Biosciences: Analyzing the Surge - StocksToTrade
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday - Sahm
Bright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders - TipRanks
Bright Minds Seizure Treatment Trial Wraps Up - timothysykes.com
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):